Hyperkalaemia in Heart Failure.

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• Hyperkalemia is common in heart failure (HF), often exacerbated by RAAS inhibitors and angiotensin-neprilysin inhibitors.
• Comorbidities like diabetes and chronic kidney disease increase hyperkalemia risk in HF patients.
• Limited effective therapies previously hindered optimal HF treatment due to hyperkalemia concerns.

Purpose of the Study:

• To review novel potassium-binding resins for managing hyperkalemia in heart failure.
• To assess the potential of these agents in facilitating guideline-directed medical therapy.

Main Methods:

• Review of clinical data on patiromer sorbitex calcium and sodium zirconium cyclosilicate.
• Analysis of their efficacy and tolerability in hyperkalemia management.
• Evaluation of their role in optimizing RAAS inhibition in HF patients.

Main Results:

• Patiromer and sodium zirconium cyclosilicate demonstrate promise in managing recurrent hyperkalemia.
• These novel resins show potential for improving tolerability of key HF therapies.
• Their use may allow for achievement of target doses of RAAS inhibitors.

Conclusions:

• Novel potassium binders offer a new therapeutic option for hyperkalemia in HF.
• These agents can help overcome treatment limitations imposed by hyperkalemia.
• Optimized medical therapy for HF patients with hyperkalemia may be achievable.